State Street SPDR S&P Biotech ETF
679 hedge funds and large institutions have $6.63B invested in State Street SPDR S&P Biotech ETF in 2023 Q3 according to their latest regulatory filings, with 63 funds opening new positions, 184 increasing their positions, 246 reducing their positions, and 92 closing their positions.
5.38% more ownership
Funds ownership: 112.14% → 117.52% (+5.4%)
5% less funds holding
Funds holding: 713 → 679 (-34)
8% less capital invested
Capital invested by funds: $7.22B → $6.63B (-$587M)
11% less funds holding in top 10
Funds holding in top 10: 19 → 17 (-2)
25% less repeat investments, than reductions
Existing positions increased: 184 | Existing positions reduced: 246
27% less call options, than puts
Call options by funds: $1.32B | Put options by funds: $1.8B
32% less first-time investments, than exits
New positions opened: 63 | Existing positions closed: 92
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$202M |
| 2 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
+$113M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$99.9M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$71.9M |
| 5 |
Squarepoint
New York
|
+$67.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$204M |
| 2 |
Jane Street
New York
|
-$73.9M |
| 3 |
EPFB
Employees Provident Fund Board
Shah Alam,
Malaysia
|
-$60.1M |
| 4 |
Twin Tree Management
Dallas,
Texas
|
-$40M |
| 5 |
HF
HRT Financial
New York
|
-$27.6M |
XBI Hedge Fund Activity: Q3 2023 in Review
679 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q3 2023, worth a combined $6.63B — down 8.1% from $7.22B a quarter earlier.
Sellers outnumbered buyers: 92 funds closed out of XBI and 63 opened new positions — a net loss of 29 holders — while 246 trimmed existing stakes and 184 added.
The largest buyer was Goldman Sachs, adding an estimated $202M. The largest seller was Bank of America, cutting an estimated $204M.
- 679 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q3 2023, down from 713 in Q2 2023.
- Funds reported $6.63B of State Street SPDR S&P Biotech ETF stock for Q3 2023, down 8.1% quarter-over-quarter.
- 63 funds opened new State Street SPDR S&P Biotech ETF positions in Q3 2023 and 92 closed out, a net change of -29 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q3 2023 was Goldman Sachs, an estimated $202M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q3 2023 was Bank of America, an estimated $204M sold.
Based on aggregated 13F filings for Q3 2023.